Cognition Therapeutics Aligns with FDA on Pivotal Trial Design for Zervimesine in DLB Psychosis
CGTX has more than doubled off its 52-week low of $0.25.
Summary
Cognition Therapeutics received official FDA feedback, confirming alignment on the design of a pivotal Phase 3 trial for zervimesine in DLB psychosis, setting a clear path for its lead drug candidate.
Key Events · Product Development and Regulatory · CGTX
-
FDA Alignment on Pivotal Trial
The FDA has agreed that psychosis associated with Dementia with Lewy Bodies (DLB) could be an approvable outcome and aligned on key aspects of a pivotal trial design for zervimesine.
-
Pivotal Trial Design Details
The Phase 3 study is expected to enroll DLB patients experiencing psychosis symptoms, including those on stable off-label antipsychotics, randomized to receive once-daily oral zervimesine or placebo for nine months.
-
Novel Primary Endpoint
The company will collaborate with the FDA on the analytical and statistical details for using the Neuropsychiatric Inventory (NPI) as a novel primary endpoint for the pivotal trial.
-
Registrational Program Timeline
The registrational program for zervimesine in DLB psychosis is expected to commence in mid-2027.
Analysis · CGTX · Life Sciences
This 8-K confirms the receipt of official written feedback from the FDA, detailing the alignment on key aspects of a pivotal Phase 3 trial for zervimesine in Dementia with Lewy Bodies (DLB) psychosis. This provides a clear regulatory path and trial design for their lead candidate, addressing a significant unmet medical need. The FDA's agreement on DLB psychosis as an approvable outcome and the use of a novel primary endpoint (NPI) are critical de-risking steps for the company.
At the time of this filing, CGTX was trading at $1.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $147.7M. The 52-week trading range was $0.25 to $3.83. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.